Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

MLA

Sun, Chaoyang, et al. Rational Combination Therapy with PARP and MEK Inhibitors Capitalizes on Therapeutic Liabilities in RAS Mutant Cancers. May 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od.......325..178aa845aef29eb9319de95287a53ec5&authtype=sso&custid=ns315887.

APA

Sun, C., Fang, Y., Yin, J., Chen, J., Ju, Z., Zhang, D., Chen, X., Vellano, C. P., Jeong, K. J., Ng, P. K.-S., Eterovic, A. K. B., Bhola, N. H., Lu, Y., Westin, S. N., Grandis, J. R., Lin, S.-Y., Scott, K. L., Peng, G., Brugge, J., & Mills, G. B. (2017). Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.

Chicago

Sun, Chaoyang, Yong Fang, Jun Yin, Jian Chen, Zhenlin Ju, Dong Zhang, Xiaohua Chen, et al. 2017. “Rational Combination Therapy with PARP and MEK Inhibitors Capitalizes on Therapeutic Liabilities in RAS Mutant Cancers,” May. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od.......325..178aa845aef29eb9319de95287a53ec5&authtype=sso&custid=ns315887.